Drug delivery strategies for therapy of visceral leishmaniasis

Bibliography

• Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999;12:62-8
   PubMed Web of Science ®Google Scholar
• Dube A, Singh N, Sundar S, Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in-vitro and in-vivo experimental models. Parasitol Res 2005;96:216-23
   PubMed Web of Science ®Google Scholar
• Kumari S, Kumar A, Samant M, Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets 2008;9:938-47
   PubMed Web of Science ®Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319
   PubMed Web of Science ®Google Scholar
• Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed 2006;1:417-32
   PubMed Web of Science ®Google Scholar
• Braunwald E, Fauci AS, Hauser SL. Harrison's manual of medicine. McGraw-Hill, New York; 2001
   Google Scholar
• Pearson RD, De Queiroz Sousa A. Principles and practice of infectious diseases. Churchill Livingstone, London, 1990
   Google Scholar
• Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci 1999;112:2993-3002
   PubMed Web of Science ®Google Scholar
• Rittig MH, Bogdan C. Leishmania-host-cell interaction: complexities and alternative views. Parasitology 2000;16:292-7
   Web of Science ®Google Scholar
• Rittig MG, Burmester GR, Krause A. Coiling phagocytosis: when the zipper jams, the cup is deformed. Trends Microbiol 1998;6:384-8
   PubMed Web of Science ®Google Scholar
• Bogdan C, Rollinghoff M. How do protozoan parasites survive inside macrophages? Parasitol Today 1999;15:22-8
   PubMedGoogle Scholar
• Handman E. Cell biology of Leishmania. Adv Parasitol 1999;44:1-39
   PubMed Web of Science ®Google Scholar
• Mosser DM, Vlassara H, Edelson PJ, Cerami A. Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation end products. J Exp Med 1987;165:140-5
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edelson PJ. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 1987;327:329-31
   PubMed Web of Science ®Google Scholar
• Alexander J, Russell DG. The interaction of Leishmania species with macrophages. Adv Parasitol 1992;31:175-254
   PubMed Web of Science ®Google Scholar
• Ilg T. Proteophosphoglycans of Leishmania. Parasitol Today 2000;16:489-97
   PubMedGoogle Scholar
• Mengeling BJ, Beverley SM, Turco SJ. Designing glycoconjugate biosynthesis for an insidious intent: phosphoglycan assembly in Leishmania parasites. Glycobiology 1997;7:878-80
   Google Scholar
• Piani A, Ilg T, Elefanty AG, Leishmania major proteophosphoglycan is expressed by amastigotes and has an immunomodulatory effect on macrophage function. Microbes Infect 1999;1:589-99
   PubMed Web of Science ®Google Scholar
• Ilgoutz SC, McConville MJ. Function and assembly of the Leishmania surface coat. Int J Parasitol 2001;31:899-908
   PubMed Web of Science ®Google Scholar
• Peters C, Aebischer T, Stierhof YD, The role of macrophage receptors in adhesion and uptake of Leishmania mexicana amastigotes. J Cell Sci 1995;108:3715-24
   PubMed Web of Science ®Google Scholar
• Moll H, Flohe S, Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol 1995;25:693-9
   PubMed Web of Science ®Google Scholar
• Chang KP. Cellular and molecular mechanisms of intracellular symbiosis in leishmaniasis. Int Rev Cytol 1983;14:267-305
   Google Scholar
• Antoine JC, Prina E, Lang T, Courret N. The biogenesis and properties of the parasitophorous vacuoles that harbor Leishmania in murine macrophages. Trends Microbiol 1998;6:392-401
   PubMed Web of Science ®Google Scholar
• Murray HW. Cellular resistance to protozoal Infection. Annu Rev Med 1986;37:61-9
   PubMed Web of Science ®Google Scholar
• Russell DG. Of microbes and macrophages: entry, survival and persistence. Curr Opin Immunol 1995;7:479-84
   PubMed Web of Science ®Google Scholar
• Chatterjee KD. Parasitology and helminthology . Chatterjee Medical Publishers, Calcutta; 1976
   Google Scholar
• Prasad LS. Kalaazar. Indian J Pediatr 1999;66:539-46
   PubMedGoogle Scholar
• Shargel L, Yu BC. Applied biopharmaceutics and pharmacokinetics. Appleton and Lange, Connecticut; 1993
   Google Scholar
• Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7
   PubMed Web of Science ®Google Scholar
• Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998;351:1928-9
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Marty P. Recent understanding in treatment of visceral leishmaniasis. J Postgrad Med 2003;49:61-8
   PubMedGoogle Scholar
• Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Ind J Med Res 2006;123:345-52
   PubMed Web of Science ®Google Scholar
• Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985;27:916-20
   PubMed Web of Science ®Google Scholar
• Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987;36:197-201
   PubMed Web of Science ®Google Scholar
• Roychoudhury J, Ali N. Sodium stibogluconate: therapeutic use in the management of leishmaniasis. Indian J Biochem Biophys 2008;45:16-22
   Web of Science ®Google Scholar
• Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009;14:2317-36
   PubMed Web of Science ®Google Scholar
• Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004;279:39925-32
   PubMed Web of Science ®Google Scholar
• Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:167-70
   PubMed Web of Science ®Google Scholar
• Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 2003;19:232-9
   PubMed Web of Science ®Google Scholar
• Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991;39:314-6
   PubMedGoogle Scholar
• Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 1991;45:435-41
   PubMed Web of Science ®Google Scholar
• Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007;14:1153-69
   PubMed Web of Science ®Google Scholar
• Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703
   PubMed Web of Science ®Google Scholar
• Sundar S. Treatment of visceral leishmaniasis. Med Microbiol Immunol (Berl) 2001;190:89-92
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002;15:593-8
   PubMed Web of Science ®Google Scholar
• Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994;344:1599-600
   PubMed Web of Science ®Google Scholar
• Thakur CP, Sinha GP, Sharma V, Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life. Indian J Pediatr 1993;60:29-36
   PubMedGoogle Scholar
• Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 1994;19:560
   PubMed Web of Science ®Google Scholar
• Seaman J, Boer C, Wilkinson R, Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21:188-93
   PubMed Web of Science ®Google Scholar
• Bowden RA, Cays M, Gooley T, Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal G, Sinha PR, Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-7
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(2):133-44
   PubMedGoogle Scholar
• Bern C, Adler-Moore J, Berenguer J, Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24
   PubMed Web of Science ®Google Scholar
• Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004;71:787-94
   PubMed Web of Science ®Google Scholar
• Thakur CP, Pandey AK, Sinha GP, Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996;90:319-22
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002A;66:143-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003A;37:800-4
   PubMed Web of Science ®Google Scholar
• Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996;173:762-5
   PubMed Web of Science ®Google Scholar
• Sundar S, Goyal AK, More DK, Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B lipid complex. Ann Trop Med Parasitol 1998;92:755-64
   PubMed Web of Science ®Google Scholar
• Dietze R, Milan EP, Berman JD, Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993;17:981-6
   PubMed Web of Science ®Google Scholar
• Dietze R, Fagundes SM, Brito EF, Treatment of kala-azar in Brazil with amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995;89:309-11
   PubMed Web of Science ®Google Scholar
• Den Boer ML, Alvar J, Davidson RN, Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009;14:395-410
   PubMed Web of Science ®Google Scholar
• Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995;81:421-5
   PubMed Web of Science ®Google Scholar
• Maarouf M, de Kouchkovsky Y, Brown S, In-vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 1997;232:339-48
   PubMed Web of Science ®Google Scholar
• Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990;84:221-5
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81
   PubMed Web of Science ®Google Scholar
• Thakur CP, Olliaro P, Gothoskar S, Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86:615-6
   PubMed Web of Science ®Google Scholar
• Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995;89:219-23
   PubMed Web of Science ®Google Scholar
• Jha TK, Olliaro P, Thakur CP, Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5
   PubMed Web of Science ®Google Scholar
• Seaman J, Pryce D, Sondorp HE, Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993;168:715-20
   PubMed Web of Science ®Google Scholar
• Melaku Y, Colin SM, Keus K, at al. Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77:89-94
   PubMed Web of Science ®Google Scholar
• Thakur CP, Olliaro P, Gothoskar S, Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86:615-6
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kanyok TP, Pandey AK, A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:429-31
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J, New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6
   PubMed Web of Science ®Google Scholar
• Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6
   PubMed Web of Science ®Google Scholar
• Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 1995;66:39-82
   PubMed Web of Science ®Google Scholar
• Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphophocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 2002;81:151-7
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Sindermann H, Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003B;22:434-8
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Jha TK, Sundar S, Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004;38:217-21
   PubMed Web of Science ®Google Scholar
• Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001;6:928-34
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Oral miltefosine for indian visceral leishmaniasis. N Engl J Med 2002B;347:1739-46
   PubMed Web of Science ®Google Scholar
• Chapman WL Jr, Hanson WL, Waits VB, Kinnamon KE. Antileishmanial activity of selected compounds in dogs experimentally infected with Leishmania donovani. Rev Inst Med Trop Sao Paulo 1979;21:189-93
   PubMedGoogle Scholar
• White MR, Chapman WL Jr, Hanson WL. Chemotherapy of experimental visceral leishmaniasis in the opossum. J Parasitol 1989;75:176-8
   PubMed Web of Science ®Google Scholar
• Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004;10:307-15
   PubMedGoogle Scholar
• Dietze R, Carvalho SF, Valli LC, Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• Croft SL. In-vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today 1986;2:64-9
   PubMedGoogle Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52
   PubMed Web of Science ®Google Scholar
• Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-87
   PubMedGoogle Scholar
• Bangham AD. Liposomes: realizing their promise. Hosp Pract (Off Ed) 1992;27:51-6, 61-2
   PubMed Web of Science ®Google Scholar
• Kshirsagar NA, Pandya SK, Kirodian BG, Sanath S. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 2005;51(1):5-14
   Google Scholar
• Abra RM, Hunt CA. Liposome disposition in-vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 1981;666:493-503
   PubMed Web of Science ®Google Scholar
• de Duve C, de Barsy T, Poole B, Commentary. Lysosomotropic agents. Biochem Pharmacol 1974;23:2495-531
   PubMed Web of Science ®Google Scholar
• Alving CR, Weldon JS, Munnell JF, Hanson WL. Liposomes in leishmaniasis: The lysosome connection. In: Gregoriadis G, Poste G, Senior J , editors, Receptor-mediated targeting of drugs. Plenum Press, New York and London; 1984. p. 317-31
   Google Scholar
• Black CD, Watson GJ, Ward RJ. The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg 1977;71:550-2
   PubMed Web of Science ®Google Scholar
• New RR, Chance ML, Thomas SC, Antileishmanial activity of antimonials entrapped in liposomes. Nature 1978;272:55-6
   PubMed Web of Science ®Google Scholar
• Alving CR, Steck EA, Chapman WL, Therapy of leishmaniasis: superior efficacies of liposome encapsulated drugs (antimonial compounds/phospholipids/model membranes/parasites). Proc Nati Acad Sci 1978;75:2959-63
   PubMed Web of Science ®Google Scholar
• New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371-81
   PubMed Web of Science ®Google Scholar
• Chapman WL Jr, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984;45:1028-30
   PubMed Web of Science ®Google Scholar
• Berman JD, Hanson WL, Chapman WL, Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agent Chemother 1986;30:847-51
   PubMed Web of Science ®Google Scholar
• Oliva G, Gradoni L, Ciaramella P, Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995;36:1013-9
   PubMed Web of Science ®Google Scholar
• Cauchetier E, Paul M, Rivollet D, Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int J Parasitol 2000;30:777-83
   PubMed Web of Science ®Google Scholar
• Schettini DA, Costa Val AP, Souza LF, Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome encapsulated meglumine antimoniate. Braz J Med Biol Res 2005;38:1879-83
   PubMed Web of Science ®Google Scholar
• Ribeiro RR, Moura EP, Pimentel VM, Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob Agent Chemother 2008;52:2564-72
   PubMed Web of Science ®Google Scholar
• Schettini DA, Ribeiro RR, Demicheli C, Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int J Pharm 2006;315:140-7
   PubMed Web of Science ®Google Scholar
• Dey T, Anam K, Afrin F, Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother 2000;44:1739-42
   PubMed Web of Science ®Google Scholar
• Pal S, Ravindran R, Ali N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob Agent Chemother 2004;48:3591-3
   PubMed Web of Science ®Google Scholar
• Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. The J Immun 2008B;181:1386-98
   PubMed Web of Science ®Google Scholar
• Khattab MA, Farr SJ, Taylor G, Kellaway IW. The in-vitro characterisation and biodistribution of some non-ionic surfactant coated liposomes in the rabbit. J Drug Target 1995;3:39-49
   PubMed Web of Science ®Google Scholar
• Proulx ME, Desormeaux A, Marquis J, Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 2001;45:2623-7
   PubMed Web of Science ®Google Scholar
• Amselem S, Yogev A, Zawoznik E, Emulsomes, a novel drug delivery technology. Proc Int Symp Control Release Bioactive Mater 1994;21:1368-9
   Google Scholar
• Amselem S, Friedman D. Solid fat nanoemulsions. US5662932; 1997
   Google Scholar
• Gupta S, Vyas SP. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007;15:206-17
   PubMed Web of Science ®Google Scholar
• Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007;15:437-44
   PubMed Web of Science ®Google Scholar
• Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv 2008;5:805-23
   PubMed Web of Science ®Google Scholar
• Gombotz WR, Pettit DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem 1995;6:332-51
   PubMed Web of Science ®Google Scholar
• Townsed R, Zutshi WA, Bekersky I. Biodistribution of 4-(14)C]cholesterol-Ambisome following a single intravenous administration to rats. Drug Metab Dispos 2001;29:681-5
   PubMed Web of Science ®Google Scholar
• Saxena S, Ghosh PC. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigates infected mice. Pharm Res 2000;17:1236-42
   PubMed Web of Science ®Google Scholar
• Kratz F, Roth T, Fichiner I, In-vitro and in-vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB- 435 mamma carcinoma model. J Drug Target 2000;8:305-18
   PubMed Web of Science ®Google Scholar
• Ordóñez-Gutiérrez L, Espada-Fernández R, Dea-Ayuela MA, In-vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 2007;30:325-9
   PubMed Web of Science ®Google Scholar
• Stjärnkvist P, Artursson P, Brunmark A, Biodegradable microspheres. VIII. Killing of Leishmania donovani in cultured macrophages by microparticle-bound primaquine. Int J Pharm 1987;40:215-22
   Web of Science ®Google Scholar
• Dea-Ayuela MA, Rama-Iniguez S, Sa´nchez-Brunete JA, Anti-leishmanial activity of a new formulation of amphotericin B. Tropical Med Int Health 2004;9:981-90
   PubMed Web of Science ®Google Scholar
• Sa´nchez-Brunete JA, Dea MA, Rama S, Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004;48:3246-52
   PubMed Web of Science ®Google Scholar
• Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007;2:16
   PubMedGoogle Scholar
• Espuelas MS, Legrand P, Loiseau PM, In-vitro antileishmanial activity of amphotericin B loaded in poly (ϵ-caprolactone) nanospheres. J Drug Target 2002;10:593-9
   PubMed Web of Science ®Google Scholar
• Gaspar R, Préat V, Roland M. Nanoparticles of polyisohexylcyanoacrylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity. Int J Pharm 1991;68:111-9
   Web of Science ®Google Scholar
• Gaspar R, Oppredoes F, Preat V, Drug targeting with polyalkylcyanoacrylate nanoparticles: in-vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann Trop Med Parasitol 1992;86:41-9
   PubMed Web of Science ®Google Scholar
• Rodrigues JM Jr, Croft SL, Fessi H, The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol 1994;45:223-8
   PubMedGoogle Scholar
• Rodrigues JM Jr, Fessi H, Bories C, Primaquine-loaded polylactide nanoparticles: physicochemical study and acute tolerance in mice. Int J Pharm 1995;126:253-60
   Web of Science ®Google Scholar
• Fouarge M, Dewulft M, Couvreur P, Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis. J Microencapsul 1989;6:29-34
   PubMed Web of Science ®Google Scholar
• Durand R, Paul M, Rivollet D, Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int J Parasitol 1997A;27:1361-7
   PubMed Web of Science ®Google Scholar
• Durand R, Paul M, Rivollet D, Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite 1997B;4:331-6
   PubMed Web of Science ®Google Scholar
• Cauchetier E, Paul M, Rivollet D, Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis. Ann Trop Med Parasitol 2003;97:259-68
   PubMed Web of Science ®Google Scholar
• Manandhar KD, Yadav TP, Prajapati VK, Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008;62:376-80
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Florence A. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Int Sci 1995;58:1-55
   Web of Science ®Google Scholar
• Gregoriadis G. Liposomes Technology. Boca Raton, CRC Press, London; 1993
   Google Scholar
• Arora R, Jain CP. Advances in niosome as a drug carrier: a review. Asian J Pharm 2007;1:29-39
   Google Scholar
• Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm 1999;185:23-5
   PubMed Web of Science ®Google Scholar
• Carter KC, Mullen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob Agent Chemother 2001;45:3555-9
   PubMed Web of Science ®Google Scholar
• Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agent Chemother 1998;42:2722-5
   PubMed Web of Science ®Google Scholar
• Carter KC, Baillie AJ, Mullen AB. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol 1999;6:61-5
   PubMedGoogle Scholar
• Williams DA, Carter KC, Baillie AJ. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in-vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J Drug Target 1995;3:1-7
   PubMed Web of Science ®Google Scholar
• Hunter CA, Dolan TF, Coombs GH, Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 1988;40:161-5
   PubMed Web of Science ®Google Scholar
• Nieto J, Alvar J, Mullen AB, Pharmacokinetics, toxicities and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003;47:2781-7
   PubMed Web of Science ®Google Scholar
• Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1986;38:502-5
   PubMed Web of Science ®Google Scholar
• Williams D, Mullen AB, Baillie AJ, Carter KC. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol 1998;50:1351-6
   PubMed Web of Science ®Google Scholar
• Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:2089-92
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996;9:512-31
   PubMed Web of Science ®Google Scholar
• Nicoletti S, Seifert K, Gilbert IH. N-(2-hydroxypropyl)methacrylamide–amphotericin B (HPMA–AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents 2009;33:441-8
   PubMed Web of Science ®Google Scholar
• Koczan G, Ghose AC, Mookerjee A, Hudecz F. Methotrexate conjugate with branched polypeptide influences Leishmania donovani infection in-vitro and in experimental animals. Bioconjug Chem 2002;13:518-24
   PubMed Web of Science ®Google Scholar
• Nan A, Croft SL, Yardley V, Ghandehari H. Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release 2004;94:115-27
   PubMed Web of Science ®Google Scholar
• Auger MJ, Ross JA, In: Lewis CE, McGee JOD, editors, The natural immune system: the macrophage. Oxford University Press, New York; 1992. p. 2-74
   Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29-40
   PubMed Web of Science ®Google Scholar
• Najjar VA. Biological and biochemical characteristics of the tetrapeptide tuftsin, Thr-Lys-Pro-Arg. Adv Exp Med Biol 1979;121:131-47
   PubMedGoogle Scholar
• Fridkin M, Gottlieb P. Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol Cell Biochem 1981;41:73-97
   PubMed Web of Science ®Google Scholar
• Constantopoulos A, Najjar VA. Tuftsin, a natural and general phagocytosis stimlating peptide affecting macrophages and polymorphonuclear granulocytes. Cytobios 1972;6:97-100
   Google Scholar
• Nishioka K, Constantopoulos A, Satoh PS, The characteristics, isolation and synthesis of the phagocytosis stimulating peptide tuftsin. Biochem Biophys Res Commun 1972;47:172-9
   PubMed Web of Science ®Google Scholar
• Fridkin M, Stabinsky Y, Zakuth V, Spirer Z. Tuftsin and some analogs: synthesis and interaction with human polymorphonuclear leukocytes. Biochim Biophys Acta 1977;496:203-11
   PubMed Web of Science ®Google Scholar
• Bar-Shavit Z, Stabinsky Y, Fridkin M, Goldman R. Tuftsin-macrophage interaction: specific binding and augmentation of phagocytosis. J Cell Physiol 1979;100:55-62
   PubMed Web of Science ®Google Scholar
• Gupta CM, Haq W. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Methods Enzymol 2005;391:291-304
   PubMed Web of Science ®Google Scholar
• Guru PY, Agarwal AK, Singha UK, Drug targetting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 1989;254:204-8
   Web of Science ®Google Scholar
• Agrawal AK, Agrawal A, Pal A, Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target 2002;10:41-5
   PubMed Web of Science ®Google Scholar
• Barratt G, Tenu JP, Yapo A, Peti JF. Preparation and characterisation of liposomes containmg mannosylated phospholipids capable of targeting drugs to macrophages. Biochim Biophys Acta 1986;862:153-64
   PubMed Web of Science ®Google Scholar
• Muller CD, Schuber F. Neo-mannosylated liposomes: synthesis and interaction with mouse kupffer cells and resident peritoneal macrophages. Biochim Biophys Acta 1989;986:97-105
   PubMed Web of Science ®Google Scholar
• Harashima H, Kiwada H. Liposomal targeting and drug delivery: kinetic consideration. Adv Drug Deliv Rev 1996;19:425-44
   Web of Science ®Google Scholar
• Banerjee G, Nandi G, Mahato SB, Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38:145-50
   PubMed Web of Science ®Google Scholar
• Kole L, Das L, Das PK. Synergistic effect of interferon-g and mannosylated liposome incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis 1999;180:811-20
   PubMed Web of Science ®Google Scholar
• Mitra M, Mandal AK, Chatterjee TK, Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 2005;13:285-93
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Das L, Kole L, Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J Infect Dis 2004;189:1024-34
   PubMed Web of Science ®Google Scholar
• Dasgupta D, Chakraborty P, Basu MK. Ligation of Fc receptor of macrophages stimulates protein kinase C and anti-leishmanial activity. Mol Cell Biochem 2000;209:1-8
   PubMed Web of Science ®Google Scholar
• Veerareddy PR, Vobalaboina V, Ali N. Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres. J Drug Target 2009;17:140-7
   PubMed Web of Science ®Google Scholar
• Chan-Bacab MJ, Pena-Rodriguez LM. Plant natural products with leishmanicidal activity. Nat Prod Rep 2001;18:674-88
   PubMed Web of Science ®Google Scholar
• Fournet A, Munoz V. Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr Top Med Chem 2002;2:1215-37
   PubMedGoogle Scholar
• Muhammad I, Dunbar DC, Khan SI, Antiparasitic alkaloids from Psychotria klugii. J Nat Prod 2003;66:962-7
   PubMed Web of Science ®Google Scholar
• Rao KV, Kasanah N, Wahyuono S. Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. J Nat Prod 2004;67:1314-8
   PubMed Web of Science ®Google Scholar
• Sairafianpour M, Christensen J, Staerk D. Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2 quinones from Perovskia abrotanoides: new source of tanshinones. J Nat Prod 2001;64:1398-403
   PubMed Web of Science ®Google Scholar
• Torres-Santos EC, Lopes D, Oliveira RR. Antileishmanial activity of isolated triterpenoids from Pourouma guianensis. Phytomedicine 2004;11:114-20
   PubMed Web of Science ®Google Scholar
• Fuchino H, Koide T, Takahashi M, New sesquiterpene lactones from Elephantopus mollis and their leishmanicidal activities. Planta Med 2001;67:647-53
   PubMed Web of Science ®Google Scholar
• Barata LE, Santos LS, Ferri PH, Antileishmanial activity of neolignans from Virola species and synthetic analogues. Phytochemistry 2000;55:589-95
   PubMed Web of Science ®Google Scholar
• Kayser O, Kiderlen AF, Laatsch H, Croft SL. In-vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Trop 2000;77:307-14
   PubMedGoogle Scholar
• Chen M, Zhai L, Christensen SB, Inhibition of fumarate reductase in Leishmania major and Leishmania donovani by chalcones. Antimicrob Agents Chemother 2001;45:2023-9
   PubMed Web of Science ®Google Scholar
• Lunardi F, Guzela M, Rodrigues AT, Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob Agents Chemother 2003;47:1449-51
   PubMed Web of Science ®Google Scholar
• Davis AJ, Kedzierski L. Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 2005;6:163-9
   PubMedGoogle Scholar
• Lala S, Gupta S, Sahu NP, Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly D,L-lactide nanoparticles against experimental leishmaniasis. J Drug Target 2006;14:171-9
   PubMed Web of Science ®Google Scholar
• Lala S, Pramanick S, Mukhopadhyay S, Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 2004;12:165-75
   PubMed Web of Science ®Google Scholar
• Tyagi R, Lala S, Verma AK, Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target 2005;13:161-71
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mandal S, Sinha J, Quercetin: Critical evaluationas an antileishmanial agent in-vivo in hamsters using different vesicular delivery modes. J Drug Target 2002;10:573-8
   PubMed Web of Science ®Google Scholar
• Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent in both liposomal and niosomal forms. J Antimicrob Chemother 1999;44:791-4
   PubMed Web of Science ®Google Scholar
• Sinha J, Raay B, Das N, Bacopasaponin C: critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv 2002;9:55-62
   PubMed Web of Science ®Google Scholar
• Raay B, Medda S, Mukhopadhyay S, Basu MK. Targeting of piperine intercalated in mannose coated liposomes in experimental leishmaniasis. Indian J Biochem Biophys 1999;36:248-51
   PubMed Web of Science ®Google Scholar
• Veerareddy PR, Vobalaboina V, Nahid A. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 2004;59:194-7
   PubMed Web of Science ®Google Scholar
• Sinha J, Mukhopadhyay S, Das N, Basu MK. Targeting of liposomal andrographolide to L. donovani infected macrophages in-vivo. Drug Deliv 2000;7:209-13
   PubMed Web of Science ®Google Scholar
• Banerjee G, Bhaduri AN, Basu MK. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochem Med Metab Biol 1994;53:1-7
   PubMedGoogle Scholar
• Mamot C, Drummond DC, Hong K, Liposome- based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003;6:271-9
   PubMed Web of Science ®Google Scholar
• Forssen E, Willis M. Ligand-targeted liposomes. Adv Drug Deliv Rev 1998;29:249-71
   PubMed Web of Science ®Google Scholar
• Fre´zard F, Martins PS, Barbosa MCM, New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimoniate and sodium stibogluconate. J Inorg Biochem 2008;102:656-65
   PubMed Web of Science ®Google Scholar
• Bryceson A. Pentamidine-induced diabetes mellitus. East Afr Med J 1968;45:110-7
   PubMedGoogle Scholar
• Scott JA, Davidson RN, Moody AH, Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg 1992;86:617-9
   PubMed Web of Science ®Google Scholar
• Loiseau PM, Imbertie L, Bories C, Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations. Antimicrob Agent Chemother 2002;46:1597-601
   PubMed Web of Science ®Google Scholar
• Hazra B, Saha AK, Ray R, Antiprotozoal activity of diospyrin towards Leishmania donovani. Trans R Soc Trop Med Hyg 1987;81:738-41
   PubMed Web of Science ®Google Scholar
• Ray S, Hazra B, Mittra B, Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 1998;54:994-9
   PubMed Web of Science ®Google Scholar
• Yardley V, Snowdon D, Croft S, Hazra B. In-vitro activity of diospyrin and derivatives against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Phytother Res 1996;10:559-62
   Web of Science ®Google Scholar
• Croft SL, Evans AT, Neal RA. The activity of plumbagin and other electron carriers against Leishmania donovani and Leishmania mexicana amazonensis. Ann Trop Med Parasitol 1985;79:651-3
   PubMed Web of Science ®Google Scholar
• Fournet A, Angelo A, Munoz V. Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as treatment of cutaneous leishmaniasis. J Ethnopharmacol 1992;37:159-64
   PubMed Web of Science ®Google Scholar
• Borris RP, Schaeffer JM. In: Nigg HN, Seigler D, editors, Phytochemical resources for medicine and agriculture. Plenum Press, New York; 1992. p. 117-58
   Google Scholar
• Fournet A, Angelo A, Muñoz V, Antileishmanial activity of a tetralone isolated from Ampelocera edentula, a Bolivian plant used as a treatment for cutaneous leishmaniasis. Planta Med 1994A;60:8-12
   PubMed Web of Science ®Google Scholar
• Mahiou V, Roblot F, Hocquemiller R, New prenylated quinones from Peperomia galioides. J Nat Prod 1996;59:694-7
   PubMed Web of Science ®Google Scholar
• Camacho MR, Kirby GC, Warhurst DC, Oxoaporphine alkaloids and quinones from Stephania dinklagei and evaluation of their antiprotozoal activities. Planta Med 2000A;66:478-80
   PubMed Web of Science ®Google Scholar
• Mahiou V, Roblot F, Hocquemiller R, New aporphine alkaloids from Guatteria foliosa. J Nat Prod 1994;57:890-5
   PubMed Web of Science ®Google Scholar
• Queiroz EF, Roblot F, Hocquemiller R, Pessoine and spinosine, two catecholic berbines from Annona spinescens. J Nat Prod 1996;59:438-40
   PubMed Web of Science ®Google Scholar
• Fevrier A, Ferreira ME, Fournet A, Acetogenins and other compounds from Rollinia emarginata and their antiprotozoal activities. Planta Med 1999;65:47-9
   PubMed Web of Science ®Google Scholar
• Fournet A, Muñoz V, Manjon AM, Active antihelminitic alkaloids: active in-vitro against Leishmanic tropica the protozoa involved in leishmaniasis. J Ethnopharmacol 1988;24:327-35
   PubMedGoogle Scholar
• Fournet A, Barrios AA, Munoz V, Effect of some bisbenzylisoquinoline alkaloid on American Leishmania sp. in BALB/c mice. Phytother Res 1993A;7:281-4
   Web of Science ®Google Scholar
• Mahiou V, Roblot F, Fournet A, Hocquemiller R. Bisabenzylisoquinoline alkaloids from Guatteria boliviana (Annonaceae). Phytochemistry 2000;54:709-16
   PubMed Web of Science ®Google Scholar
• Fournet A, Hocquemiller R, Roblot F, Chimanines, novel substituted quinolines, isolated from Bolivian antiparasitic plant, Galipea longiflora. J Nat Prod 1993B;56:1547-52
   Web of Science ®Google Scholar
• Fournet A, Barrios AA, Munoz V, 2-Substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob Agents Chemother 1993C;37:859-63
   PubMed Web of Science ®Google Scholar
• Fournet A, Gantier JC, Gautheret A, The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J Antimicrob Chemother 1994B;33:537-44
   PubMed Web of Science ®Google Scholar
• Kam TS, Sim KM, Koyano T, Komiyama K. Leishmanicidal alkaloids from Kopsia griffithii. Phytochemistry 1999;50:75-9
   Web of Science ®Google Scholar
• Moretii C, Sauvain M, Lavaud C, A novel antiprotozoal aminosteroid from Saracha punctata. J Nat Prod 1998;61:1390-3
   PubMed Web of Science ®Google Scholar
• Kam TS, Sim KM, Koyano T, Cytotoxic and leishmanicidal aminoglycosteroids and aminosteroids from Holarrhena curtisii. J Nat Prod 1998;61:1332-6
   PubMed Web of Science ®Google Scholar
• Kapil A. Piperine: a potent inhibitor of Leishmania donovani promastigotes in-vitro. Planta Med 1993;59:474
   PubMed Web of Science ®Google Scholar
• Kapil A, Sharma S, Wahidullah S. Leishmanicidal activity of 2-benzoxazolinone from Acanthus illicifolius in-vitro. Planta Med 1994;60:187-8
   PubMed Web of Science ®Google Scholar
• Khaliq T, Misra P, Gupta S, Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett 2009;19:2585-6
   PubMed Web of Science ®Google Scholar
• Misra P, Khaliq T, Dixit A, Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother 2008;62:998-1002
   PubMed Web of Science ®Google Scholar
• Di Giorgio C, Lamidi M, Delmas F, Antileishmanial activity of quinovic acid glycosides and cadambine acid isolated from Nauclea diderrichii. Planta Med 2006;72:1396-402
   PubMed Web of Science ®Google Scholar
• Tandon JS, Srivastava V, Guru PY. Iridoids: a new class of leishmanicidal agents from Nyctanthes arbortristis. J Nat Prod 1991;54:1102-4
   PubMed Web of Science ®Google Scholar
• Puri A, Saxena RP, Sumati, Immunostimulant activity of picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, and its protective action against Leishmania donovani infection in hamsters. Planta Med 1992;58:528-32
   Web of Science ®Google Scholar
• Ray S, Majumder HK, Chakravarty AK, Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J Nat Prod 1996;59:27-9
   PubMed Web of Science ®Google Scholar
• Hocquemiller R, Cortex D, Arango GJ, Isolation and synthesis of espintanol, a novel antiparasitic monoterpene. J Nat Prod 1991;54:443-52
   Google Scholar
• Mahiou V, Roblot F, Hocquemiller R, Piperogalin, a new prenylated diphenol from Peperomia galioides. J Nat Prod 1995;58:324-8
   PubMed Web of Science ®Google Scholar
• Fournet A, Munoz V, Roblot F, Antiprotozoal activity of dehydrozaluzanin C, a sesquiterpene lactone isolated from Munnozia maronii (Asteraceae). Phytother Res 1993D;7:111-5
   Web of Science ®Google Scholar
• Villaescusa L, Diaz-Lanza AM, Gasquet M, Antiprotozoal activity of sesquiterpene from Jasonia glutinosa. Pharm Biol 2000;38:176-80
   PubMed Web of Science ®Google Scholar
• Schmeda-Hirschmann G, Razmilic I, Sauvain M, Antiprotozoal activity of jatrogrossidione from Jatropha grossidentata and jatrophone from Jatropha isabellii. Phytother Res 1996;10:375-8
   Web of Science ®Google Scholar
• Richomme P, Godet MC, Foussard F, A novel leishmanicidal labdane from Polyalthia macropoda. Planta Med 1991;57:552-4
   PubMed Web of Science ®Google Scholar
• Garcia-Granados A, Linan E, Martinez A, In-vitro action of ent-manoyl oxides against Leishmania donovani. J Nat Prod 1997;60:13-6
   Web of Science ®Google Scholar
• Loukaci A, Kayser O, Bindseil KU, New trichothecenes from Holarrhena floribunda. J Nat Prod 2000;63:52-56
   PubMed Web of Science ®Google Scholar
• Camacho MDR, Mata R, Castaneda P, Bioactive compounds from Celaenodredon mexicanum. Planta Med 2000B;66:462-8
   Google Scholar
• Wright CW, Phillipson JD. Natural products and the development of selective antiprotozoal drugs. Phytother Res 1990;4:127-39
   Web of Science ®Google Scholar
• Delmas F, Di Giorgio C, Elias R, Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in-vitro. Planta Med 2000;66:343-7
   PubMed Web of Science ®Google Scholar
• Majester-Savornin B, Elias R, Diaz-Lanza AM, Saponins of the ivy plant, Hedera helix, and their leishmanicidic activity. Planta Med 1991;57:260-2
   PubMed Web of Science ®Google Scholar
• Dutta A, Ghoshal A, Mandal D, Racemoside A, an anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani. J Med Microbiol 2007B;56:1196-204
   PubMed Web of Science ®Google Scholar
• Maes L, Berghe DV, Germonprez N, In-vitro and in-vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob Agents Chemother 2004A;48:130-6
   PubMed Web of Science ®Google Scholar
• Maes L, Germonprez N, Quirijnen L, Comparative activities of the triterpene saponin Maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother 2004B;48:2056-60
   PubMed Web of Science ®Google Scholar
• Ding N, Yahara S, Nohara T. Structure of mimengosides A and B, new triterpenoid glycosides from Buddlejae flos produced in China. Chem Pharm Bull 1992;40:780-2
   Web of Science ®Google Scholar
• Emam AM, Moussa AM, Faure R, Isolation and biological study of a triterpenoid saponin, mimengoside A, from the leaves of Buddleja madagascariensis. Planta Med 1996;62:92-3
   PubMed Web of Science ®Google Scholar
• Chen M, Christensen SB, Blom J, Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother 1993;37:2550-6
   PubMed Web of Science ®Google Scholar
• Chen M, Christensen SB, Theander TG, Kharazmi A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother 1994;38:1339-44
   PubMed Web of Science ®Google Scholar
• Kayser O, Kiderlen AF, Folkens U, Koldziej H. In-vitro leishmanicidal activity of aurones. Planta Med 1999;65:316-9
   PubMed Web of Science ®Google Scholar
• Christensen SB, Ming C, Andersen L, An antileishmanial chalcone from Chinese licorice roots. Planta Med 1994;60:121-3
   PubMed Web of Science ®Google Scholar
• Sahpaz S, Bories CH, Loiseau PM, Cytotoxic and antiparasitic activity from Annona senegalensis seeds. Planta Med 1994;60:538-40
   PubMed Web of Science ®Google Scholar
• Waechter AI, Yaluff G, Inchausti A, Leishmanicidal and trypanocidal activities of acetogenins isolated from Annona glauca. Phytother Res 1998;12:541-4
   Web of Science ®Google Scholar
• Rasmussen HB, Christensen SB, Kvist LP, Absolute configuration and antiprotozoal activity of minquartynoic acid. J Nat Prod 2000;63:1295-6
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar A, Gupta P, Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res 2008;102:561-5
   PubMed Web of Science ®Google Scholar
• Sarkar A, Sen R, Saha P, An ethanolic extract of leaves of Piper betle (Paan) Linn mediates its antileishmanial activity via apoptosis. Parasitol Res 2008;102:1249-55
   PubMed Web of Science ®Google Scholar
• Lakshmi V, Pandey K, Kapil A, In-vitro and in-vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani. Phytomedicine 2007;14:36-42
   PubMed Web of Science ®Google Scholar
• Ndjakou Lenta B, Vonthron-Sénécheau C, Fongang Soh R, In-vitro antiprotozoal activities and cytotoxicity of some selected Cameroonian medicinal plants. J Ethnopharmacol 2007;111:8-12
   PubMed Web of Science ®Google Scholar
• Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M. Aloevera leaf exudate induces a caspase-independent cell death in Leishmania donovani promastigotes. J Med Microbiol 2007A;56:629-36
   PubMed Web of Science ®Google Scholar
• Ganguly S, Bandyopadhyay S, Bera A, Chatterjee M. Antipromastigote activity of an ethanolic extract of leaves of Artemisia indica. Indian J Pharmacol 2006;38:64-5
   Google Scholar
• Singh N, Mishra PK, Kapil A, Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis. J Ethnopharmacol 2005;98:83-8
   PubMed Web of Science ®Google Scholar
• Camacho MDR, Phillipson JD, Croft SL, Screening of plant extracts for antiprotozoal and cytotoxic activities. J Ethnopharmacol 2003;89:185-91
   PubMed Web of Science ®Google Scholar
• Weniger B, Robledo S, Arango GJ, Antiprotozoal activities of Colombian plants. J Ethnopharmacol 2001;78:193-200
   PubMed Web of Science ®Google Scholar
• Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidioides. Phytother Res 2001;15:122-6
   PubMed Web of Science ®Google Scholar
• Mittal N, Gupta N, Saksena S, Protective effect of picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus. Life Sci 1998;63:1823-34
   PubMed Web of Science ®Google Scholar
• Martin T, Villaescusa L, Gasque M, Screening for protozoocidal activity of Spanish plants. Pharm Biol 1998;36:56-62
   Web of Science ®Google Scholar
• Iwu MM, Jackson JE, Tally JD, Klayman DL. Evaluation of plant extracts for antileishmanial activity using a mechanism-based radiorespirometric microtechnique (RAM). Planta Med 1992;58:436-41
   PubMed Web of Science ®Google Scholar
• Singha UK, Guru PY, Sen AB, Tandon JS. Antileishmanial activity of traditional plants against Leishmania donovani in golden hamsters. Int J Pharmacog 1992;30:289-95
   Google Scholar